The maker of a leading over-the-counter antacid has withdrawn its application for approval of the drug in China because a clinical trial of the product in that country was marred by “major protocol deviations.”
Researchers for the company, Reckitt Benckiser, maker of Gaviscon, had published a report on the study in 2015 in the journal Alimentary Pharmacology & Therapeutics. But the journal has now retracted the article, “Randomised clinical trial: The clinical efficacy and safety of an alginate‐antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China,” at the behest of the drug maker.
According to the notice: Continue reading “Sufficiently serious” issues in study prompt company to yank drug approval application in China


A toxicology journal has issued an expression of concern for a group of papers about the controversial herbicide glyphosate after concluding that some of the authors didn’t adequately disclose their ties to the maker of the product. 
A journal that retracted three papers earlier this year because of concerns that one of the authors had asked conference presenters to cite them has republished the articles, saying that it has “inconclusive evidence of improper behavior.”
The wheels of scientific publishing turn slowly … but they do (sometimes) turn.

